Annals of nuclear medicine · 2025
Blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Jabri Amna Juma, Cooke Jennie, Cournane Seán, Healy Marie-Louise
Аннотация
PURPOSE: Radioiodine (131I) dosimetry is used to maximise tumour dose while reducing the chances of toxicity. High thyroid-stimulating-hormone (TSH) levels are required for 131I treatment, achieved through hormone withdrawal or intramuscular injection of recombinant human TSH (rhTSH). Both approaches have shown equivalent results, with the rhTSH approach reported to reduce morbidity and avoid hypothyroidism. There are established differences in 131I biokinetics using each method. This clinical cohort study investigated if pretherapy iodine biokinetics as measured using a dosimetry protocol without a dose of rhTSH are predictive of post therapy biokinetics in patients prepared with rhTSH injection.
METHODS: Thirteen patients with differentiated thyroid cancer (DTC) were recruited. An adaptation of the European Association of Nuclear Medicine (EANM) dosimetry protocol was conducted at St James's Hospital, Ireland. The maximum tolerable activity (MTA) was calculated using the EANM, Association of Physics in Medicine (AIFM) and Traino models, after administering 131I, and subsequent whole-body (WB) dose-rate measurements and blood-sampling were carried out. The MTA estimated from pre-therapeutic (PT) 131I tracer administration (6.07 ± 2.46 MBq) was compared to during therapy (DT) administration (3.88 ± 0.16 GBq).
RESULTS: The PT WB residence-time overestimated the DT with a difference of - 7.72 ± 8.13% (p = 0.007), while no significant difference is reported between the blood residence-time (1.13 ± 6.49%, p = 0.559). The EANM model reported the lowest difference of 1.73 ± 4.83% (p = 0.241) in MTA.
CONCLUSION: This study validated the feasibility of using dosimetry in euthyroid patients to predict therapeutic 131I biokinetics in DTC patients prepared with rhTSH.
METHODS: Thirteen patients with differentiated thyroid cancer (DTC) were recruited. An adaptation of the European Association of Nuclear Medicine (EANM) dosimetry protocol was conducted at St James's Hospital, Ireland. The maximum tolerable activity (MTA) was calculated using the EANM, Association of Physics in Medicine (AIFM) and Traino models, after administering 131I, and subsequent whole-body (WB) dose-rate measurements and blood-sampling were carried out. The MTA estimated from pre-therapeutic (PT) 131I tracer administration (6.07 ± 2.46 MBq) was compared to during therapy (DT) administration (3.88 ± 0.16 GBq).
RESULTS: The PT WB residence-time overestimated the DT with a difference of - 7.72 ± 8.13% (p = 0.007), while no significant difference is reported between the blood residence-time (1.13 ± 6.49%, p = 0.559). The EANM model reported the lowest difference of 1.73 ± 4.83% (p = 0.241) in MTA.
CONCLUSION: This study validated the feasibility of using dosimetry in euthyroid patients to predict therapeutic 131I biokinetics in DTC patients prepared with rhTSH.